AbbVie | ABBV - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.63B 54M 2026-06
Abbott USD 3.6B 330M 2026-06
ALKERMES USD 196.64M 67.96M 2026-06
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.8B 735M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Coherus Biosciences USD 15M 6.26M 2025-12
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.19B 75M 2026-06
J&J USD 6.42B 381M 2026-06
Medtronic 2.96B 9M 2025-12
Merck USD 2.67B 180M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Pacira USD 83.88M 7.99M 2026-03
Perrigo USD 267.3M 11.4M 2026-03
Pfizer USD 3.41B 496M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
UCB EUR 1.47B 193M 2025-12
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 156.6M 34M 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06
Zoetis USD 588M 31M 2026-03